Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / December / New Genetic Test Targets Rare X-Linked Movement Disorder / Notecards
Neurology Genetics and epigenetics Omics Research and Innovations Molecular Pathology

New Genetic Test Targets Rare X-Linked Movement Disorder

A targeted assay, presented at AMP 2025, identifies disease-specific TAF1 variants that standard panels often miss.

12/03/2025 News 3 min read
article Full Article Summary Notecard

Share

  1. New genetic test for X-linked dystonia-parkinsonism (XDP) developed.

  2. Test targets specific DNA changes in the TAF1 gene.

  3. XDP mainly affects men of Filipino ancestry.

  4. Symptoms include muscle spasms, tremors, and impaired movement.

  5. Traditional methods miss specific genetic changes; new test improves diagnosis.

  6. Management focuses on symptomatic treatments like therapy and medication.

  7. Increased testing awareness could help at-risk populations.

  8. No current cure for XDP is available.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.